J&J Names New CEO
The new CEO is likely focused on continuing the industry-leading innovative strategy.
The new CEO is likely focused on continuing the industry-leading innovative strategy.
Johnson & Johnson (JNJ) announced on Aug. 19 that Joaquin Duato will replace Alex Gorsky as CEO in early 2022. We don’t expect any change to our fair value estimate or economic moat rating based on the succession plan. The announcement does come a little earlier than we had expected, since Gorsky is only 61 years old; he named family health issues as playing a role in his decision to step down.
Given Duato’s 30-plus years at J&J, including his recently successful strategy work in the drug and consumer divisions, we believe he will continue the industry-leading innovative strategy pursued under Gorsky. Further, we expect continued steady growth based on a diverse group of product lines. However, we don’t expect the extralong tenure typical of a J&J CEO, as Duato is 59 years old. With strong leaders surrounding him, including Jennifer Taubert (head of the drug unit) and Ashley McEvoy (head of the device unit) at the two largest business segments and Joe Wolk as CFO, Duato has a solid support structure for current business operations as well as leading internal candidates for the eventual CEO succession.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days. |
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.